Építés alatt – nem éles oldal
Belépés
Csak meghívásosFázis nélkül

Vagus Nerve Stimulation (VNS) in Spinal Cord Injury (SCI) Adaptive Follow-On Study

A legfontosabb adatok

Ki végzi
The University of Texas at Dallas
Hol
Dallas és Richardson (Egyesült Államok)Mind a 2 helyszín megnézése
Azonosító
Állapot
Csak meghívásos
Résztvevők
20 fő, tervezett
Kezdés
2024. aug. 29.
Várható befejezés
2028. máj.
A vizsgálat típusa
Beavatkozással járó, 4 csoport
A vizsgált kezelések
  • Active VNS
A regiszteradat frissítve
2026. június 4.

Ki vehet részt

MI-összefoglaló

A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.

The trial is looking for adults with long-term spinal cord injury who finished phase 2 of the SCI EFS study (NCT04288245) and still have their VNS device. They get vagus nerve stimulation with exercises for arms, legs, bladder control or feeling.

Életkor
18 Years to 64 Years
Nem
All sexes can join.
A betegség stádiuma
Chronic (long-term) spinal cord injury. Leg track: able to walk but with walking problems. Bladder track: urine problems from the injury, can partly start urinating on their own, and use a catheter from time to time. Sensory track: reduced feeling on baseline tests.
Korábbi kezelés
Must have completed phase 2 of the SCI EFS study (NCT04288245). The VNS device must not have been removed.
Biomarker vagy leletérték
Sensory track: US-NSA score <92 points, two-point discrimination fingertip score >5mm or palm score >15mm, Tactile Discrimination Test score <16points, or Semmes-Weinstein Monofilaments score >3.61g.

A részvétel fő kizáró okai

  • Another active treatment trial now or within 7 days before joining.
  • Serious brain injury, active cancer, recent fainting or recent swallowing problems.
  • Pregnant, breastfeeding, or women who could become pregnant and do not use birth control.
  • Being suicidal, not speaking English, or needing diathermy (deep heat treatment).
  • Bladder track: permanent catheter or severe or repeated autonomic dysreflexia (sudden dangerous rise in blood pressure).

A regiszter feltételei, szó szerint

Mind a 32 feltétel megnézéseKevesebb

Egyéb feltételek

  • General Inclusion Criteria:
  • Completed phase 2 of the SCI EFS study (NCT04288245)
  • Willing to comply with procedures for the entire duration of the study (study protocol compliance)
  • Provision of signed and dated informed consent form
  • Access to reliable communication and internet connections (for those intending to complete sessions at home)
  • Has not had their VNS device explanted; General Exclusion Criteria:
  • Concurrent participation in another active interventional trial or participation in an active interventional trial within 7 days prior to enrollment
  • Any medical condition or other circumstances that might interfere with their ability to return for follow-up visits in the judgment of the Investigator
  • Any condition which would preclude adequate evaluation of device's safety and performance in the judgment of the Investigator
  • Individuals who have a change in medical condition or health status such that they would meet the exclusion criteria of the EFS
  • Concomitant clinically significant brain injuries
  • Receiving any other therapy that would interfere with VNS
  • Females of childbearing potential who are either pregnant, lactating, heterosexually active, or planning to become pregnant or heterosexually active during study participation; and who are not using, or will not agree to use medically acceptable birth control methods
  • Psychiatric disorders, psychosocial, and/or cognitive impairment that would interfere with study participation, as assessed by medical evaluation
  • Participants with a current or past: (i) medical (psychiatric, non-psychiatric) condition, disease, disorder, injury, or disability; or (ii) non-medical situation or circumstance that, in the opinion of the principal investigator, study participation:; May pose a significant or undue risk to the person; Make it unlikely the person will complete all the study requirements per protocol; or; May adversely impact the integrity of the data or the validity of the study results
  • Participants with active neoplastic disease
  • Participants with significant local circulatory problems, (e.g. thrombophlebitis and lymphedema, and clinically-significant hypotension or bradycardia)
  • Participants with any medical condition or other circumstances that might interfere with their ability to return for follow-up visits in the judgment of the Investigator
  • Any condition which, in the judgment of the Investigator, would preclude adequate evaluation of device's safety and performance
  • Aphasia and other cognitive deficits may be present but participants will be excluded if are unable to understand the potential risks and benefits of the study or personally provide informed consent
  • A recent history of syncope
  • A recent history of dysphagia
  • Currently require, or are likely to require diathermy
  • Significant respiratory issues that would interfere with participation
  • Non-English speaking
  • Patients who are acutely suicidal and/or have been admitted for a suicide attempt
  • As determined by the principal investigator, is under current incarceration or legal detention; Track Specific Inclusion Criteria:; Upper Limb (UL):; 1)None; Lower Limb (LL):; 1)Ambulatory with gait impairment; Bladder Control (BC):; 1)Issues with urinary function arising from SCI, with partial voluntary initiation of voiding 2)Intermittent catheterization for bladder management; Sensory (SY):; 1)Impairment in sensory function, based on the baseline assessments below:
  • US-NSA score <92 points
  • Two-point discrimination fingertip score >5mm
  • Two-point discrimination palm score >15mm
  • Tactile Discrimination Test score <16points
  • Semmes-Weinstein Monofilaments score >3.61g; Track Specific Exclusion Criteria:; Upper Limb (UL):; 1)None; Lower Limb (LL):; 1)None; Bladder Control (BC):; 1)Indwelling catheter use 2)Participants with a history of severe or recurrent autonomic dysreflexia 3)Technical limitations that would preclude bladder ultrasonography assessments 4)Medical history that would preclude adequate evaluation of urologic outcomes; Sensory (SY):; Pain that would impede study participation

Nézd meg, megfelelhetsz-e

Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.

  • 18 és 64 év között vagy?

Helyszínek itt: Egyesült Államok

  • Baylor University Medical CenterDallas, Egyesült ÁllamokCsak meghívásos
  • Texas Biomedical Device CenterRichardson, Egyesült ÁllamokCsak meghívásos

A vizsgálatról

Mit akar kideríteni a vizsgálat

This study is an open label extension of the SCI EFS clinical trial (NCT04288245) that developed an innovative strategy to enhance recovery of motor and sensory function after neurological injury. The objectives of this study are to provide continued safety assessment for the investigational ReStore system, and to gain further estimate of the effect of Vagus Nerve Stimulation (VNS) with rehabilitative exercises in four different tracks - upper limb (UL), lower limb (LL), bladder control (BC), and sensory (SY) for participants with chronic SCI (Spinal Cord Injury).

A vizsgálat 4 csoportja

  • Upper limb (UL)A vizsgált kezelés

    Participants in this arm will receive up to 36 sessions of VNS paired with upper limb rehabilitative exercises

    Kezelés: Active VNS

  • Lower limb (LL)A vizsgált kezelés

    Participants in this arm will receive up to 36 sessions of VNS paired with lower limb rehabilitative exercises

    Kezelés: Active VNS

  • Bladder control (BC)A vizsgált kezelés

    Participants in this arm will receive up to 36 sessions of VNS paired with bladder control rehabilitative exercises

    Kezelés: Active VNS

  • Sensory (SY)A vizsgált kezelés

    Participants in this arm will receive up to 36 sessions of VNS paired with sensory rehabilitative exercises

    Kezelés: Active VNS

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
Illeszkedési kérdések
Forrás: NCT06351111: ki vehet részt
A regiszteradat frissítve
2026. június 4.